LECTURAS RECOMENDADAS

1. Jeremy .J.Y.; Angelini, G.D. et.al. Platelets, oxidant stress and erectile dysfunction: an hypothesis. En: Cardiovascular Research; 2000, 40:50-54

2. Simonsen, U.; Contreras, J. et.al. Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries. En: European Journal of Pharmacology; 2001, 412:155-169.

3. Katz, S.D., Balidemaj, K.; et.al. Acute Type 5 Phosphodiesterase Inhibition with Sildenafil Enhances Flow-Mediated Vasodilation in Patients with Chronic Heart Failure. En: Journal of the American College of Cardiology; 2000, 36(3):845-851.

4. Moreland, R.B.; Goldstein, I.; et.al. Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor: Research and Clinical Implications in Erectile Dysfunction. TEM; 1999, 10(3):97-104

5. Andersson, K-E. And Stief, C. Penile Erection and Cardiac Risk: Pathophysiologic and Pharmacologic Mechanisms. En: The American Jornal of Cardiology; 2000, 86(2A):23F-26F.

6. Takagi, M.; Mochida, H.; et.al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. En: European Journal of Pharmacology; 2001, 411:161-168

7. Phillips, B. G.; Masahiko, K.; et.al. Sympathetic Activation by Sildenafil. En: Circulation; 2000: 3068-3073

8. Herrmann, H.; Chang, G.; et. al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. En: The New England Journal of Medicine; 2000, 342(22):1622-1626

9. Zusman, R. M. Cardiovascular Data on Sildenafil Citrate. En: The American Journal of Cardiology; 1999, 83(5A):1C-20C.

10. Webb, D.J.; Freestone, S. Sildenafil Citrate and Blood-Pressure-Lowering Drugs: Results of Drug Interaction Studies with an Organic Nitrate and a Calcium Antagonist. En: The American Journal of Cardiology; 1999, 83(5A):21C-28C.

11. Conti, C.R.; Pepine, C.J.; Sweeney, M. Efficacy and Safety of Sildenafil Citrate in the Treatment of Erectile Dysfunction in Patients with Ischemic Heart Disease. En: The American Journal of Cardiology; 1999, 83(5A):29C-34C.

12. Zusman, R. M.; Morales, A.; et. al. Overall Cardiovascular Profile of Sildenafil Citrate. En: The American Journal of Cardiology; 1999, 83(5A):35C-44C.

13. Jackson, G. Sexual Intercourse and Stable Angina Pectoris. The American Journal of Cardiology; 1999, 83(5A):1C-20C.

14. DeBusk, R.; Drory, Y.; et. al. Management of Sexual Dysfunction in Patients with Cardiovascular Disease: Recommendations of the Princeton Consensus Panel. The American Journal of Cardiology; 2000, 86(2):175-181

15. Cheitlin, M.; Hutter, A. M.; et. al. Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease. En: J Am Coll Cardiol; 1999, 33:273-282

16. Chiou, W.; Chen, J.; et. al. Relaxation of corpus carvernosum and raised intracavernous pressure by berberine in rabbit. En: British Journal of Pharmacology; 1998, 125:1677-1684.

17. Feenstra J.; Van Drie-Pierik, R.; et. al. Acute Myocardial Infarction associated with Sildenafil. En: The Lancet; 1998. 352:957-962.

18. Kloner, R. A.; Jarow, J. P. Erectile Dysfunction and Sildenafil Citrate and Cardiologists. En: The American Journal of Cardiology; 1999, 83:576-582

19. Chen, J.; Chiou, WF.; et.al. Effect of the Plant-Extract Osthole on the Relaxation of Rabbit Corpus Cavernosum tissue in Vitro. En: J Urol; 2000, 163(6):1975-1980.

20. Kloner, R.A. Sex and the Patient with Cardiovascular Risk Factors: Focus on Sildenafil. En: The American Journal of Medicine; 2000, 109(9A:13S-21.